Related LncRNAs
ID	lncRNA Name	Disease	Method	Sample	Expression pattern	Dysfunction type	Description	PMID	Source
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	mutation	Genotypes of rs10757278 linked to increased risk of atherosclerotic diseases are also associated with decreased expression in PBTL of the INK4/ARF locus, near CDKN2B-AS1 locus.	19343170	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	expression	9p21.3 may promote atherosclerosis by regulating expression of ANRIL, which in turn is associated with altered expression of genes controlling cellular proliferation pathways.	19592466	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	mutation/expression	Transcripts EU741058 and NR_003529 of antisense noncoding RNA in the INK4 locus (ANRIL) were significantly increased in carriers of the risk haplotype.	20056914	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	Interaction	ANRIL abundantly expressed in atherosclerotic lesions. ANRIL DQ485454 which is not genetically determined by the 9p21 genotype was significantly correlated with MTAP expression.	20637465	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	locus	A genetic susceptibility locus.	20956613	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	mutation	Individuals homozygous for the atherosclerotic risk allele (rs3217992, A>G;rs1063192, C>T) show decreased expression of ANRIL.	21151960	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	expression	Gene expression studies have found that expression levels of CDKN2A/CDKN2B/ANRIL are co-regulated and associated with the risk haplotype and atherosclerosis severity.	21550161	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	mutation	The risk alleles for atherosclerosis-related phenotypes were consistently associated with a lower expression of ANRIL when evaluating exons 1-2. Common carotid artery stenosis was associated with a significantly lower (P<0.01) expression of ANRIL (exons 1-2). ANRIL knock-down in VSMC caused significant variation in expression of CDKN2A/B (P<0.05) and reduction of cell growth (P<0.05) in vitro.	22178423	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	mutation	Genetic variation in lncRNA genes causes disease and influences susceptibility	23791884	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	regulation	The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10.	23813974	LncRNADisease
EL0289	CDKN2B-AS1	atherosclerosis	N/A	N/A	N/A	mutation	Chr9p21 encodes the long non-coding RNA (ncRNA) antisense non-coding RNA in the INK4 locus (ANRIL). ANRIL expression is associated with the Chr9p21 genotype and correlated with atherosclerosis severity	23861667	LncRNADisease
EL0556	H19	atherosclerosis	N/A	N/A	N/A	epigenetics	The most pronounced differences of atherosclerotic plaques in DNA methylation levels were registered for a site which is located in CpG-island of imprinted gene H19.	21954592	LncRNADisease
EL0600	HULC	atherosclerosis	N/A	liver cancer	up-regulated	N/A	HULC regulated TNF-α-induced apoptosis through regulation of miR-9 expression	26981838
EL1166	RP5-833A20.1	atherosclerosis	N/A	N/A	N/A	N/A	Using microarray analysis, the authors found that long noncoding RNA RP5-833A20.1 expression was upregulated, whereas nuclear factor IA (NFIA) expression was downregulated in human acute monocytic leukemia macrophage-derived foam cells. Moreover, they showed that long noncoding RNA RP5-833A20.1 maydecreases NFIA expression by inducing hsa-miR-382-5p expression in vitro.	25265644	LncRNADisease
EL1349	TP53COR1	atherosclerosis	N/A	N/A	N/A	N/A	The expression of lincRNA-p21 was dramatically downregulated in atherosclerotic plaques of ApoE(-/-) mice, an animal model for atherosclerosis. LincRNA-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro	25156994	LncRNADisease